In Vitro Antifungal Susceptibility Profiles of Dermatophytes Isolates from Tinea Capitis in Northwest, Nigeria

Document Type : Original Research

Authors
H. Yahaya Ungo-kore 1
J. Olorunmola Ehinmidu 2
J. Ademola Onaolapo 2
O. Stephen Olonitola 3
1 Department of Pharmaceutics and Pharmaceutical Microbiology, Faculty of Pharmaceutical Sciences, Usmanu Danfodiyo University
2 Department of Pharmaceutical Microbiology, Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria
3 Department of Microbiology, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Kaduna
10.52547/iem.7.4.347
Abstract
Backgrounds: The fungal infection of tinea capitis is a common mycosis that affects the scalp superficially, especially in children. Oral treatment of this infection remains the preferred treatment process in clinical dermatology. Many antifungals available for dermatophyte treatment lead to treatment failure. Determination of antifungal susceptibility of dermatophytes in-vitro has been reported to be important to curb dermatophyte infections using effective antifungal drugs. The aim of this study was to investigate and determine in vitro minimum inhibitory concentration (MIC) of amphotericin B, ketoconazole, griseofulvin, terbinafine, and fluconazole against dermatophyte clinical isolates using agar dilution method.

Materials and Methods: In this study, in vitro susceptibilities of 32 dermatophyte clinical isolates collected from primary school pupils in Sokoto metropolis were investigated to five antifungals (fluconazole, terbinafine, ketoconzole, amphotericin B, and griseofulvin) using the CLSI agar dilution method.

Findings: The results obtained revealed that griseofulvin and terbinafine were the most potent antifungal agents among those tested.

Conclusion: Agar dilution method could be an alternative method for MIC-determination of antifungal drugs against dermatophyte species, since it is cost effective and affordable with consistent results, especially in developing countries.

Keywords

Subjects

1. Gupta, A. K., Foley, K. A., & Versteeg, S. G. (2017). New antifungal agents and new formulations against dermatophytes. Mycopathologia, 182(1–2), 127–141.
2. Leung, A. K., Hon, K. L., Leong, K. F., Barankin, B., & Lam, J. M. (2020). Tinea capitis: An updated review. Recent Patents on Inflammation & Allergy Drug Discovery, 14(1), 58–68.
3. Ferguson, L., & Fuller, L. C. (2017). Spectrum and burden of dermatophytes in children. Journal of Infection, 74, S54–S60.
4. Assob, J. C. N., Nsagha, D. S., Njouendou, A. J., Zofou, D., Sevidzem, W. F., Ketchaji, A., Chiara, A., Asangbeng, T. E., Dzemo, K. O., & Samba, B. M. (2017). Diseases in Africa: An Overview. In Medicinal Spices and Vegetables from Africa (pp. 1–69). Elsevier.
5. Deng, S., Ansari, S., Ilkit, M., Rafati, H., Hedayati, M. T., Taghizadeh-Armaki, M., Nasrollahi-Omran, A., Tolooe, A., Zhan, P., & Liao, W. (2017). In vitro antifungal susceptibility profiles of 12 antifungal drugs against 55 Trichophyton schoenleinii isolates from tinea capitis favosa patients in Iran, Turkey, and China. Antimicrobial Agents and Chemotherapy, 61(2).
6. Ghuse, V., Someshwar, S., & Jerajani, H. (2019). Patterns of culture positivity and antifungal sensitivity in dermatophytosis. MGM Journal of Medical Sciences, 6(3), 105.
7. Humphries, R. M., & Hindler, J. A. (2016). Emerging resistance, new antimicrobial agents… but no tests! The challenge of antimicrobial susceptibility testing in the current US regulatory landscape. Clinical Infectious Diseases, 63(1), 83–88.
8. Campana, E. H., Carvalhaes, C. G., Nonato, B., Antonia, M. de, Machado, O., & Gales, A. C. (2014). Comparison of MICE and Etest with CLSI agar dilution for antimicrobial susceptibility testing against oxacillin-resistant Staphylococcus spp. PLoS One, 9(4), e94627.
9. Therese, K. L., Bagyalakshmi, R., Madhavan, H. N., & Deepa, P. (2006). In-vitro susceptibility testing by agar dilution method to determine the minimum inhibitory concentrations of amphotericin B, fluconazole and ketoconazole against ocular fungal isolates. Indian Journal of Medical Microbiology, 24(4), 273.

10. Pharmacopoeia, B. (2016). British pharmacopoeia.
11. Gracia Paul, L. (2019). ERG11 Expression in Azole Resistant Candida species isolated from Diabetic Patients in a Tertiary Care Centre [PhD Thesis]. Tirunelveli Medical College, Tirunelveli.
12. Badali, H., Mohammadi, R., Mashedi, O., de Hoog, G. S., & Meis, J. F. (2015). In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs. Mycoses, 58(5), 303–307.

13. Coelho, L. M., Aquino-Ferreira, R., Maffei, C. M. L., & Martinez-Rossi, N. M. (2008). In vitro antifungal drug susceptibilities of dermatophytes microconidia and arthroconidia. Journal of Antimicrobial Chemotherapy, 62(4), 758–761.
14. Aktas, A. E., Yigit, N., Aktas, A., & Gozubuyuk, S. G. (2014). Investigation of in vitro activity of five antifungal drugs against dermatophytes species isolated from clinical samples using the E-test method. The Eurasian Journal of Medicine, 46(1), 26.
15. Newland, J. G., & Abdel-Rahman, S. M. (2009). Update on terbinafine with a focus on dermatophytoses. Clinical, Cosmetic and Investigational Dermatology: CCID, 2, 49.
16. Singal, A., Rawat, S., Bhattacharya, S. N., Mohanty, S., & Baruah, M. C. (2001). Clinico-Mycological Profile of Tinea Capitis in North India and Response to Griseofulvin. The Journal of Dermatology, 28(1), 22–26.
17. Osborne, C. S., Leitner, I., Hofbauer, B., Fielding, C. A., Favre, B., & Ryder, N. S. (2006). Biological, biochemical, and molecular characterization of a new clinical Trichophyton rubrum isolate resistant to terbinafine. Antimicrobial Agents and Chemotherapy, 50(6), 2234–2236.
18. Wingfield Digby, S. S., Hald, M., Arendrup, M. C., Hjorth, S. V., & Kofoed, K. (2017). Darier Disease Complicated by Terbinafine-resistant Trichophyton rubrum: A Case Report. Acta Dermato-Venereologica, 97(1), 139–140.
19. Dambuza, I. M., Wagener, J., Brown, G. D., & Gow, N. A. (2017). Immunology of fungal disease. Oxford Textbook of Medical Mycology, 62.
20. Tomar, R. S., Sharma, P., Sharma, A., & Mishra, R. (2015). ASSESSMENT AND EVALUATION OF METHODS USED FOR ANTIMICROBIAL ACTIVITY ASSAY: AN OVERVIEW.
21. Mikaeili, A., Kavoussi, H., Hashemian, A. H., Gheshtemi, M. S., & Kavoussi, R. (2019). Clinico-mycological profile of tinea capitis and its comparative response to griseofulvin versus terbinafine. Current Medical Mycology, 5(1), 15.
Infection Epidemiology and Microbiology
Volume 7, Issue 4
November 2021
Pages 347-356